Oncolytics Biotech Inc. (ONC.TO) TSX
Currency In CAD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CAD
Address
322 11th Avenue SW
Calgary, AB T2R 0C5
Canada
Phone
14036707380
Sector
Healthcare
Industry
Biotechnology
Employees
28
First IPO Date
June 01, 2000
| Name | Title | Pay | Year Born |
| Wayne F. Pisano | Interim Chief Executive Officer & Chairman of the Board | 311,949 | 1955 |
| John Mark Lievonen | Consultant | 25,976 | N/A |
| Allison Hagerman | Vice President of Product Development | 489,048 | N/A |
| Amy Goodowitz Levin | Vice President of Clinical Operations | 540,351 | N/A |
| Kirk J. Look | Chief Financial Officer | 675,115 | N/A |
| Thomas C. Heineman | Chief Medical Officer | 804,381 | N/A |
| Jon Patton | Director of Investor Relations & Communication | 0 | N/A |
| Christophe Degois | Vice President of Business Development | 0 | N/A |
Oncolytics Biotech Inc. is a biopharmaceutical firm in its development stage, dedicated to researching and creating medicinal therapies for cancer. The company's primary asset is pelareorep, an immunotherapeutic agent administered intravenously to combat both solid tumors and blood cancers. Oncolytics Biotech maintains a collaborative development pact with Merck KGaA and Pfizer Inc. This collaboration aims to advance pelareorep when combined with paclitaxel and avelumab—a human anti-PD-L1 antibody—specifically for addressing metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor 2-negative. Additionally, the company partners with PrECOG LLC. Established in 1998, the enterprise operates from its main office in Calgary, Canada.